Beximco Pharma sends third product to US

Sunday, 29 April 2018

Beximco Pharmaceuticals Limited has started exporting Methocarbamol to the US market. The first consignment was delivered on April 21 and it was the third product from the country's leading manufacturer and exporter of medicines. The company earlier launched Carvedilol and Sotalol in August 2016 and November 2017, respectively. Methocarbamol is generic equivalent to muscle relaxant drug Robaxin from Auxilium Pharmaceuticals. According to IQVIA market data, the US market for Methocarbamol is currently valued at US$ 23.37 million. Beximco Pharma managing director Nazmul Hassan MP says: "The export of our third product to the US further builds our presence in the world's largest pharmaceutical market." Beximco Pharma remains the only Bangladeshi company to export medicine to the US market following its manufacturing site approval by the US FDA in June 2015.